EMISPHERE TECHNOLOGIES, INC. (OTCMKTS:EMIS) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

The Company held its annual meeting of stockholders (the Annual
Meeting) on May18, 2017. The final results for each of the
matters submitted to a vote of stockholders at the Annual Meeting
are set forth below. A more detailed description of each proposal
is set forth in the Companys Proxy Statement filed with the
Securities and Exchange Commission on April14, 2017.

Proposal No.1 Election of Directors. The
stockholders elected each of the Boards nominees for director, to
serve a term expiring at the third succeeding annual meeting
after their election or until their respective successors are
duly elected and qualified, by the votes set forth in the table
below:

Proposal No.2 Advisory Approval of Executive
Compensation . The stockholders approved, on an advisory
basis, the compensation of the Companys named executive officers
by the votes set forth in the table below:

Proposal No.3 Advisory Vote on the Frequency of the
Approval of Executive Compensation. The stockholders
approved, on an advisory basis, that a stockholder vote to
approve the compensation of the Companys named executive officers
should occur every year by the votes set forth in the table
below:

Proposal No.4 Approval of the Companys 2017 Equity
Incentive Plan. The stockholders approved the Companys
2017 Equity Incentive Plan by the votes set forth in the table
below:

Proposal No.5 Ratification of Appointment of Certified
Public Accountants. The stockholders ratified, by
non-binding vote, the appointment of RSM US LLP as the Companys
independent registered accounting firm for the fiscal year ending
December31, 2017, by the votes set forth in the table below:

About EMISPHERE TECHNOLOGIES, INC. (OTCMKTS:EMIS)

Emisphere Technologies, Inc. is a commercial-stage pharmaceutical and drug delivery company. The Company, in partnership with pharmaceutical companies, develops new formulations of existing products, as well as new chemical entities, using its Eligen Technology. Its first prescription medical food product is oral Eligen B12. The Company utilizes its Eligen Technology to create new oral formulations of therapeutic agents. Its product pipeline includes prescription drug and medical food product candidates that are being developed in partnership or internally. Its preclinical programs focus on the development of oral formulations of potentially new treatments for diabetes and products in the areas of cardiovascular, appetite suppression and pain and on the development and potential expansion of nutritional supplement products. The Eligen Technology is an applicable oral drug delivery technology based on the use of synthetic chemical compounds known as Eligen delivery agents, or carriers.

EMISPHERE TECHNOLOGIES, INC. (OTCMKTS:EMIS) Recent Trading Information

EMISPHERE TECHNOLOGIES, INC. (OTCMKTS:EMIS) closed its last trading session down -0.020 at 0.450 with shares trading hands.